The cover illustrates the small-molecule-mediated control of the antitumour activity of a supramolecular bispecific T-cell engager through its disassembly.
Supramolecular engagers of tumour cells and T cells with an ‘off’ switch
The off-tumour toxicity of a supramolecular bispecific T-cell engager can be halted by disengaging T cells from the tumour cells via the disassembly of the supramolecular aggregate through the infusion of the small-molecule drug amantadine.
Published in
Bioengineering & Biotechnology
Follow the Topic
Applied Immunology
Life Sciences > Biological Sciences > Biotechnology > Applied Immunology
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in